Corticosteroids are mainly responsible for posttransplantation (Tx) osteoporosis.1 The clinical trial of deflazacort (DFZ) with a biologically equivalent dose of conventional steroid revealed a less detrimental effect on bone metabolism.2 We tried elective conversion from prednisone (PDS) to DFZ in recipients with stable graft function 1 year after post-Tx to confirm the bone-sparing effect of DFZ.